In various embodiments, the present disclosure relates to compositions and methods for preventing or treating
cancer, preventing, treating or inhibiting viral or microbial infection or replication, or preventing, treating or inhibiting other diseases. In some embodiments, the composition includes at least one of an
arginine mimetic (TA-R) or a
histidine mimetic (TA-H), or an application thereof. In some embodiments, the at least one of TA-R or TA-H is TA-R, which may include, but is not limited to, trans-4-
guanidine methylcyclohexanecarboxylic acid (TA-R1), amino (((((1r, 4r)-4-(methoxycarbonyl) cyclohexyl) methyl) amino) methylenimine
chloride (TA-R1-OMe), amino ((((1r, 4r)-4-(methoxycarbonyl) cyclohexyl) methyl) amino) methylenimine
chloride (TA-R), and TA-H (TA-R). (3-(methoxycarbonyl) cyclohexyl) methyl) amino) methyleneimine
chloride (TA-R2), cis-amino (((3-carboxycyclohexyl) methyl) amino) methyleneimine chloride (TA-R3), cis-amino (((3 (methoxycarbonyl) cyclohexyl) methyl) amino) methyleneimine chloride (TA-R3-OMe) and cis-3-(guanidinyl)
cyclopentane-1-
formic acid (TA-R4), and the compound is prepared from the following raw materials in parts by weight: (4r, 4r)-4-carboxycyclohexyl) amino) methyleneimine chloride (TA-R2), (3r, 4r)-4-carboxycyclohexyl) amino) methyleneimine chloride (TA-R3), (3r, 4r)-4-carboxycyclohexyl) amino) methyleneimine Compounds having cycloalkanes containing two or more functional groups other than cycloalkanes, derivatives thereof, salts thereof, and combinations thereof.